Skip to main content

Generic Baqsimi Availability

Last updated on Jan 11, 2023.

Baqsimi is a brand name of glucagon, approved by the FDA in the following formulation(s):

BAQSIMI (glucagon - powder;nasal)

Has a generic version of Baqsimi been approved?

No. There is currently no therapeutically equivalent version of Baqsimi available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Baqsimi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Nasal powder formulation for treatment of hypoglycemia
    Patent 10,213,487
    Issued: February 26, 2019
    Assignee(s): Eli Lilly and Company

    The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.

    Patent expiration dates:

    • February 16, 2036
      Drug product
  • Patent 10,765,602

    Patent expiration dates:

    • September 23, 2039
      Drug product
  • Patent 10,894,133

    Patent expiration dates:

    • January 3, 2038
      Drug product
  • Fluid or powdery product dispensing device
    Patent 6,938,798
    Issued: September 6, 2005
    Inventor(s): Stradella; Giuseppe
    Assignee(s): TEBRO S.A.

    A device for dispensing a substance in fluid or powder form, the device having a dispensing outlet (10), an air blaster (20) for generating a blast of air when the device is actuated, and at least one reservoir (30) containing a single dose of substance. The reservoir (30) an air inlet (31) connected to the air blaster (20), and a substance outlet (32) connected to the dispensing orifice (10), the air inlet (31) being provided with a substance retaining member (40) for retaining the substance in the reservoir (30) until it is dispensed, and the substance outlet (32) being closed off by a closure element (50). The dispenser device is configured such that the closure element (50) is a spherical element, such as a ball, force fitted into the substance outlet (32) of the reservoir (30). The device further has a mechanical opening system (60, 70, 80) co-operating with the closure element (50) for ejecting it mechanically from its closure position when the device is actuated.

    Patent expiration dates:

    • January 3, 2022
      Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • July 24, 2022 - NEW PRODUCT


Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.